Sobi signs $450M deal for rare disease drug emapalumab, boosting its inflammation, I/O pipeline
Swedish drugmaker Sobi has bought global rights to a late-stage rare disease drug from Novaimmune SA, building up its inflammation business and potentially lining up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
